BSF ENTERPRISE PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.75 GBX | -5.00% |
|
-5.00% | -53.66% |
| Apr. 12 | BSF Enterprise Plc announced that it has received £0.09 million in funding | CI |
| Apr. 11 | BSF Enterprise Gets Funding for Development of Cultivated Leather | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | - | Sales 2023 | 0.01 | Capitalization | 10.59M |
|---|---|---|---|---|---|
| Net income 2022 | - | Net income 2023 | -1M | EV / Sales 2022 | - |
| Net cash position 2022 | 830K | Net cash position 2023 | 2.16M | EV / Sales 2023 | 651,360,609 x |
| P/E ratio 2022 |
-2.79
x | P/E ratio 2023 |
-6.46
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 42.09% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -5.00% | ||
| 1 week | -5.00% | ||
| Current month | -5.00% | ||
| 1 month | -24.00% | ||
| 3 months | -51.28% | ||
| 6 months | -47.80% | ||
| Current year | -53.66% |
1 week
4.56
5.45
1 month
4.505.70
Current year
4.5012.45
1 year
4.5016.90
3 years
3.0023.88
5 years
3.0023.88
10 years
3.0023.88
| Managers | Title | Age | Since |
|---|---|---|---|
Geoffrey Baker
FOU | Founder | 67 | 18-09-04 |
Che Connon
CEO | Chief Executive Officer | 52 | - |
Graham Duncan
DFI | Director of Finance/CFO | 61 | 22-06-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Min Yang
FOU | Founder | 56 | 18-09-04 |
Geoffrey Baker
FOU | Founder | 67 | 18-09-04 |
Kian Jing Ow
BRD | Director/Board Member | 58 | 21-08-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 4.75 | -5.00% | 920,655 |
| 24-05-09 | 5 | 0.00% | 4,263 |
| 24-05-08 | 5 | 0.00% | 0 |
| 24-05-07 | 5 | 0.00% | 208,520 |
| 24-05-03 | 5 | +5.26% | 102,489 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT
More quotes
BSF Enterprise PLC is a United Kingdom-based biotechnology company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people. 3DBT has three strands of three intellectual property (IP) each with a different sector focus development and revenue timeline. 3DBTâs City-mix is an animal-free cell growth agent for culturing skin, muscle and fat cells which are used for lab-grown meat and leather production. 3DBTâs Lipopeptide Etsyl actively increases collagen production in human skin cells which can be used in cosmetic and skin care products.
Sector
Pharmaceuticals
Calendar
2025-01-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -53.66% | 6.14M | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
- Stock Market
- Equities
- BSFA Stock
